Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00169871
Status:
COMPLETED
Last Update Posted:
2007-04-23
First Post:
2005-09-13
Brief Title:
Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia
Sponsor:
CHU de Quebec-Universite Laval
Organization:
CHU de Quebec-Universite Laval
Study Overview
Official Title:
Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia
Status:
COMPLETED
Status Verified Date:
2006-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this proposal is to study the applicability of the hs-CRP assay in the assessment of CV risk in daily clinical conditions where hyperlipidemic population with or without CHD are currently evaluated
Detailed Description:
Coronary heart disease CHD is the major cause of death in the developed world Cholesterol screening has been used as a tool to identify individuals who are at increased risk of developing future coronary events but almost one-half of patients who develop myocardial infarction have either normal or only moderately increased serum cholesterol concentrations In the last years experimental and clinical evidence has demonstrated that atherosclerosis is not simply a disease of lipid deposits Rather there is growing recognition that CHD has an inflammatory component which plays a critical role in the arterial plaque rupture that triggers most episodes of coronary thrombosis In the last years C-reactive protein CRP an exquisitely sensitive marker of systemic inflammation has emerged as a powerful predictor of cardiovascular diseases in particular of CHD beyond what can be estimated by traditional risk factors The availability of high-sensitivity hs CRP assays has enabled the detection of even low-grade inflammatory responses that have previously been regarded as clinically not meaningful However for hs-CRP to make the transition from epidemiological and clinical research to the routine clinical setting several important issues must be satisfactorily addressed
Therefore the overall objective of this proposal is to study the applicability of the hs-CRP assay in the assessment of CV risk in daily clinical conditions where hyperlipidemic population with or without CHD are currently evaluated and to evaluate hs-CRP response to statins
Therefore the overall objective of this proposal is to study the applicability of the hs-CRP assay in the assessment of CV risk in daily clinical conditions where hyperlipidemic population with or without CHD are currently evaluated and to evaluate hs-CRP response to statins
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None